← 返回

肿瘤患者诊疗全程中的口腔管理:临床方案的范围综述

英文原题:Dental management of patients with cancer across the care pathway: A scoping review of clinical protocols.

查看英文原题

Dental management of patients with cancer across the care pathway: A scoping review of clinical protocols.

PubMed 2026/05/01(内容时间) Med Oral Patol Oral Cir Bucal Q2 · IF 2.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

证据支持治疗前清除的操作性共识以及治疗期间的核心支持治疗集束化措施。

中文摘要

癌症及其治疗引起的口腔并发症会损害生活质量并干扰肿瘤治疗。对整个诊疗路径中的口腔管理进行标准化至关重要。

梳理2000至2025年间,针对肿瘤患者治疗前、治疗期间及随访或生存者阶段口腔管理的操作方案、指南、流程图或结构化建议。

按照JBI指南开展范围综述,并依据PRISMA-ScR报告。于2025年10月19日检索PubMed或MEDLINE、SciELO、Scopus、Web of Science和Virtual Health Library,不限语言。使用Rayyan进行双人筛选。以标准化的逐条矩阵提取数据,并按照护阶段和肿瘤治疗方式采用叙述、表格和图示综合。未进行正式质量评价或荟萃分析。

共纳入12篇文献。内容主要集中于治疗前(11/12;91.7%),其次为随访或生存者阶段(6/12;50.0%)和治疗期间(3/12;25.0%)。一致性建议包括:治疗前进行全面评估和口腔清理;加强预防措施,包括卫生指导和局部氟化物;根据牙齿预后设定拔牙标准和愈合时间窗;以及治疗期间针对黏膜炎、口干和感染采取支持措施。现存不足包括生存者照护流程标准化有限、未能充分根据肿瘤治疗方式(放疗、化疗、HSCT或CAR-T、免疫治疗)进行个体化,以及缺乏安全时间窗、临床或血液学阈值和转诊/会诊触发条件等操作细节。

现有证据支持治疗前口腔评估清理及治疗期间核心支持措施的操作共识。为优化安全性和结局,尤其在中等收入环境中,需要制定治疗方式特异性方案,明确口腔—肿瘤科转诊路径、结合剂量和血液学指标的决策规则及随访安排。

展开英文摘要原文

Oral complications of cancer and its therapies impair quality of life and can disrupt oncologic care. Standardizing dental management across the care pathway is essential.

To map operational protocols, guidelines, algorithms, or structured recommendations for dental management of oncology patients across pre-treatment, active treatment, and follow-up or survivorship from 2000 to 2025. MATERIAL AND METHODS: Scoping review according to JBI guidance and reported with PRISMA-ScR. Searches were run in PubMed or MEDLINE, SciELO, Scopus, Web of Science, and the Virtual Health Library on October 19, 2025, without language restrictions. Dual screening was performed in Rayyan. Data were charted in a standardized per-record matrix and synthesized narratively, in tables, and with graphics by care phase and oncologic modality. No formal critical appraisal or meta-analysis was undertaken.

Twelve records were included. Coverage concentrated on pre-treatment (11 of 12; 91.7 percent), followed by follow-up or survivorship (6 of 12; 50.0 percent) and active treatment (3 of 12; 25.0 percent). Convergent recommendations included comprehensive pre-treatment assessment with sanitation, an intensified prevention bundle with hygiene instruction and topical fluorides, tooth-prognosis-based extraction criteria with defined healing windows, and supportive measures during therapy for mucositis, xerostomia, and infections. Gaps included limited standardization of survivorship pathways, insufficient personalization by oncologic modality (radiotherapy, chemotherapy, HSCT or CAR-T, immunotherapies), and scarce operational detail on safe timing windows, clinical or hematologic cutoffs, and referral or consultation triggers.

Evidence supports an operational consensus for pre-treatment clearance and a core supportive bundle during therapy. To optimize safety and outcomes, particularly in middle-income settings, modality-specific protocols with explicit dentistry-oncology referral pathways, dose- and hematology-informed decision rules, and defined follow-up schedules are warranted.

论文信息

作者
Espada-Salgado FM、Iuga MM、Capellino-Gambetta AR
单位
Facultad de Ciencias de la Salud Universidad Privada de Tacna Av. Jorge Basadre Grohmann s/n Pocollay Postal code 23000. Tacna, Perú ferespada@virtual.upt.pe.
文献类型
范围综述
期刊
Medicina oral, patologia oral y cirugia bucal2026 May 1
原文标识
PubMed 41578908 · DOI 10.4317/medoral.27886